Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
复制标题
DOI：
10.1093/cid/ciab381
复制
发表时间：
2021-12-01
影响因子：
11.8
通讯作者：
Schaal, Heiner
中科院分区：
文献类型：
--
作者：
Mueller, Lisa;Andree, Marcel;Schaal, Heiner
背景。严重急性呼吸综合征冠状病毒2（SARS - CoV - 2）大流行促使多种疫苗得以研发。尽管在疫苗接种活动中老年人被优先考虑，但关于80岁以上最脆弱接种人群所引发免疫反应的实际数据仍然不足。
方法。我们对两个年龄组进行了一项队列研究，即60岁以下的年轻接种者和80岁以上的老年接种者，以比较他们对BNT162b2新型冠状病毒肺炎疫苗第一剂和第二剂的抗体反应。
结果。尽管两组中的大多数参与者都产生了针对SARS - CoV - 2刺突蛋白的特异性免疫球蛋白G抗体滴度，但老年参与者的滴度明显较低。尽管老年参与者在第二次免疫后抗体水平的增幅较高，但该组的绝对平均滴度仍低于……
Background. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to the development of various vaccines. Real-life data on immune responses elicited in the most vulnerable group of vaccinees older than age 80 years old are still underrepresented despite the prioritization of the elderly in vaccination campaigns.Methods. We conducted a cohort study with 2 age groups, young vaccinees below the age of 60 years and elderly vaccinees over the age of 80 years, to compare their antibody responses to the first and second dose of the BNT162b2 coronavirus disease 2019 vaccination.Results. Although the majority of participants in both groups produced specific immunoglobulin G antibody titers against SARS-CoV-2 spike protein, titers were significantly lower in elderly participants. Although the increment of antibody levels after the second immunization was higher in elderly participants, the absolute mean titer of this group remained lower than the